|Articles|May 13, 2015
- NSCLC (Issue 7)
- Volume 7
- Issue 2
Characteristics of Additional KRAS Subsets in Lung Cancer
Author(s)John Heymach, MD, PhD
John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, discusses the characteristics of three more KRAS subsets in lung cancer, which researchers discovered in a recent study.
John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, discusses the characteristics of three more KRAS subsets in lung cancer, which researchers discovered in a recent study.
<<<
Articles in this issue
over 10 years ago
MET as a Secondary Driver in Lung Cancerover 10 years ago
MiR-34a Link to PD-L1 May Mean New Immunotherapy in NSCLCover 10 years ago
More Endpoints Not Necessarily Merrier in NSCLC Drug Trialsover 10 years ago
Combining Bevacizumab With EGFR TKIs in Lung Cancerover 10 years ago
US-Cuban Partnership Developing Anticancer Vaccine for NSCLCRelated Content
Advertisement
